Personalized medicine for HLA-associated drug-hypersensitivity reactions

Personalized Medicine
Mandvi BharadwajLyudmila Kostenko

Abstract

Multiple genetic and nongenetic factors can modify the action of a drug, resulting in varied responses to a particular drug across different individuals. Personalized medicine incorporates the comprehensive knowledge of these factors to facilitate the selection of optimal therapy, reduce adverse drug reactions, increase patient compliance and increase the efficiency of therapy. Pharmacogenomics, which integrates the knowledge of an individual's genetic make-up for diagnostic decisions or therapeutic interventions is closely linked to personalized medicine, and is being increasingly used to prevent adverse drug reactions. There are various reports on genetic associations between particular HLA allotypes and drug hypersensitivities and the strongest associations reported thus far, are with the reverse transcriptase inhibitor, abacavir and HLA-B*5701, the gout prophylactic allopurinol and HLA-B*5801 and the antiepileptic carbamazepine and B*1502, providing a defined disease trigger and suggesting a general mechanism for these associations. Recognizing the strong HLA association, the US FDA has recommended genetic testing before starting abacavir and carbamazepine therapies. To incorporate HLA testing for other drug hypersensitivit...Continue Reading

References

Jul 9, 1977·Lancet·K L Schmidt, C Mueller-Eckhardt
Apr 1, 1992·Annals of the Rheumatic Diseases·A HietaharjuH Frey
Jul 1, 1991·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·E AlamartineF Berthoux
Jul 25, 1985·The New England Journal of Medicine·F KuttennI Mowszowicz
Jan 1, 1988·Annual Review of Pharmacology and Toxicology·L R PohlJ G Kenna
Oct 1, 1986·Tissue Antigens·J C RoujeauN Duédari
Apr 28, 1973·Lancet·D A BrewertonR D Sturrock
Mar 9, 1973·Nature·M F Caffrey, D C James
Aug 18, 1984·British Medical Journal·H A Cameron, L E Ramsay
Sep 1, 1982·Archives of Ophthalmology·S OhnoM Aizawa
Jul 1, 1995·The Journal of Investigative Dermatology·M Hertl, H F Merk
Nov 10, 1994·The New England Journal of Medicine·J C Roujeau, R S Stern
Jan 23, 1993·BMJ : British Medical Journal·C K FairleyI Boyd
Mar 1, 1993·The Annals of Pharmacotherapy·F Arellano, J A Sacristán
Feb 1, 1996·International Archives of Allergy and Immunology·N HaasB M Czarnetzki
Jan 1, 1996·European Journal of Immunology·E PadovanH U Weltzien
Apr 16, 1996·Proceedings of the National Academy of Sciences of the United States of America·F BoisgeraultA Toubert
May 1, 1997·Antimicrobial Agents and Chemotherapy·M B FalettoS S Good
May 1, 1997·Journal of the American Academy of Dermatology·R PellicanoP Gasparini
Jul 1, 1997·The Journal of Clinical Investigation·B SchnyderW J Pichler
Jun 1, 1997·European Journal of Immunology·E PadovanH U Weltzien
Feb 5, 1998·Archives of Dermatology·N HaasB M Henz
Jun 3, 1998·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·A RomanoR Manna
Jul 29, 1998·International Journal of Dermatology·M D KamaliahN Nazmi
Apr 13, 1999·The Journal of Allergy and Clinical Immunology·J QuiralteT Carrillo
Feb 7, 2001·Journal of Medical Microbiology·A Ebringer, C Wilson

❮ Previous
Next ❯

Citations

Oct 12, 2017·Pharmacogenomics·Simone Negrini, Laurent Becquemont
Sep 28, 2012·Science China. Life Sciences·YaLan ZhangWen Tan
May 16, 2018·Frontiers in Genetics·Kim N T TonMartin A Kennedy
Jun 22, 2014·Experimental Biology and Medicine·Narat J EungdamrongAngela M Christiano

❮ Previous
Next ❯

Methods Mentioned

BETA
acetylator

Software Mentioned

PyMOL

Related Concepts

Related Feeds

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

© 2022 Meta ULC. All rights reserved